The pharmaceutical giant said its profit was impacted by a large charge related to its recent merger with Schering-Plough, but still managed to top analyst estimates. Looking forward, Merck lifted the lower end of its 2010 earn…
Tiny, little-known biotech Clinical Data has developed a potential blockbuster drug called Vilazodone. If OK’d, it would be the first new depression treatment in 15 years. Its potential is so huge that several Big Pharmas are s…
Federal investigators are looking into allegations that major drug companies, including Merck, AstraZeneca, Bristol-Myers Squibb and GlaxoSmithKline, paid bribes overseas to boost sales and accelerate approvals.
…
Looking for stocks that could move fast? Hilary Kramer, editor of GameChangerStocks.com, recommends taking a look at two lesser-known pharmaceuticals, Shire and Medco Health Systems, that she says will benefit greatly in the near term.
Continue reading Under the Radar: Two Ways to Profit from Growth in Pharmaceuticals
Under the Radar: Two Ways to Profit from Growth in Pharmaceuticals originally appeared on DailyFinance on Wed, 22 Sep 2010 15:30:00.
Filed Under: Investing, JP Morgan Chase, Johnson & Johnson, Pfizer, Merck
Intel Capital has made a new set of investments through its $200 million Invest in America Technology Fund. Four software and chip-design businesses that have collectively received more than $30 million from the patriotic fund:…